Relative Bioavailability Study of GSK1265744 Formulations

This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods)
in healthy adult subjects. During each period, subjects will receive a single dose of
GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours
(8 days) and safety assessments will be performed. Each period will be separated by a
washout period of at least 14 days and a follow-up visit will occur 10 to 14 days after the
last dose of study drug.

Clinical Trial Conditions: Infections, Human Immunodeficiency Virus and Hepatitis

Treatments in this Clinical Trial : GSK1265744 Na Salt Tablets, GSK1265744 Free Acid Nanomilled Capsules, GSK1265744 Free Acid Micronized Capsules

Clinical Trial Phase: Phase 1

Eligible Clinical Trial Participant Age : Between 18 years to 64 years

Can Healthy Volunteers Participate: Yes

Clinical Trial Lead Sponsor: ViiV Healthcare

Detailed Clinical Trial Description: This is a single-center, randomized, open-label, balanced, 3 way crossover study (3 periods)
in healthy adult subjects. During each period, subjects will receive a single dose of
GSK1265744 oral formulation in the fasted state and serial PK sampling for up to 168 hours
(8 days) and safety assessments will be performed. Each period will be separated by a
washout period of at least 14 days and a follow-up visit will occur 10 to 14 days after the
last dose of study drug.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01648257